Damir Nizamutdinov1, Eileen M Stock2, Jad A Dandashi3, Eliana A Vasquez3, Ying Mao4, Samantha Dayawansa1, Jun Zhang5, Erxi Wu6, Ekokobe Fonkem1, Jason H Huang7. 1. Texas A&M Health Science Center College of Medicine, Temple, Texas, USA; Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. 2. Cooperative Studies Program Coordinating Center (CSPCC), VA Maryland Health Care System, Perry Point, Maryland, USA. 3. Texas A&M Health Science Center College of Medicine, Temple, Texas, USA. 4. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. 5. Department of Neurosurgery, PLA General Hospital, Beijing, China. 6. Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. 7. Texas A&M Health Science Center College of Medicine, Temple, Texas, USA; Department of Neurosurgery, Baylor Scott and White Health Care, Temple, Texas, USA. Electronic address: Jason.Huang@bswhealth.org.
Abstract
OBJECTIVE: Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with dismal survival. This study aims to examine the prognostic value of primary tumor sites and race on survival outcomes. METHODS: Patient data obtained from the Scott and White Hospital Brain Tumor Registry (1976-2013) were stratified according to sex, age, race, primary tumor site, vital status, and survival. RESULTS: Of the 645 patients, 580 (89.9%) were diagnosed with GBM not otherwise specified (GBM NOS), 57 (8.8%) with GBM, and 8 (1.2%) with giant-cell GBM. Most were male (53.5%), aged 50 years or older (78.7%). The white population had the highest GBM prevalence (87.1%) and the lowest overall survival versus all other race groups (6.6% vs. 30.1%; P < 0.01). The black population had a relatively low prevalence of GBM (5.9%) and the greatest overall survival versus all others (47.4% vs. 7.3%; P < 0.01). Primary tumor sites located in the temporal (25.8% vs. 20.2%; P = 0.03), occipital (8.1% vs. 2.9%; P = 0.05), and parietal lobes (24.2% vs. 20.8%; P = 0.05) had a greater occurrence in surviving individuals. The overall survival for men versus women was (62.9% vs. 37.1%; P = 0.12). CONCLUSIONS: Black racial background and temporal, occipital, or parietal primary tumor sites are suggestive of positive survival outcomes. Conversely, white racial background with primary tumor sites in the brain overlapping and NOS areas seem to be associated with negative outcomes and decreased survival. Thus, racial background and primary tumor site may be useful prognostic factors in patients with GBM.
OBJECTIVE:Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with dismal survival. This study aims to examine the prognostic value of primary tumor sites and race on survival outcomes. METHODS:Patient data obtained from the Scott and White Hospital Brain Tumor Registry (1976-2013) were stratified according to sex, age, race, primary tumor site, vital status, and survival. RESULTS: Of the 645 patients, 580 (89.9%) were diagnosed with GBM not otherwise specified (GBM NOS), 57 (8.8%) with GBM, and 8 (1.2%) with giant-cell GBM. Most were male (53.5%), aged 50 years or older (78.7%). The white population had the highest GBM prevalence (87.1%) and the lowest overall survival versus all other race groups (6.6% vs. 30.1%; P < 0.01). The black population had a relatively low prevalence of GBM (5.9%) and the greatest overall survival versus all others (47.4% vs. 7.3%; P < 0.01). Primary tumor sites located in the temporal (25.8% vs. 20.2%; P = 0.03), occipital (8.1% vs. 2.9%; P = 0.05), and parietal lobes (24.2% vs. 20.8%; P = 0.05) had a greater occurrence in surviving individuals. The overall survival for men versus women was (62.9% vs. 37.1%; P = 0.12). CONCLUSIONS: Black racial background and temporal, occipital, or parietal primary tumor sites are suggestive of positive survival outcomes. Conversely, white racial background with primary tumor sites in the brain overlapping and NOS areas seem to be associated with negative outcomes and decreased survival. Thus, racial background and primary tumor site may be useful prognostic factors in patients with GBM.
Authors: K M Pińa Batista; I F Vega; S A de Eulate-Beramendi; Jcg Morales; A Kurbanov; D Asnel; A Meilan; A Astudillo Journal: Folia Neuropathol Date: 2015 Impact factor: 2.038
Authors: B M Ellingson; A Lai; R J Harris; J M Selfridge; W H Yong; K Das; W B Pope; P L Nghiemphu; H V Vinters; L M Liau; P S Mischel; T F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2012-09-20 Impact factor: 3.825
Authors: M Esteller; M Toyota; M Sanchez-Cespedes; G Capella; M A Peinado; D N Watkins; J P Issa; D Sidransky; S B Baylin; J G Herman Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254
Authors: Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee Journal: Genes Dev Date: 2007-11-01 Impact factor: 11.361
Authors: Shota Tanaka; Fredric B Meyer; Jan C Buckner; Joon H Uhm; Elizabeth S Yan; Ian F Parney Journal: J Neurosurg Date: 2012-11-23 Impact factor: 5.115
Authors: Martina Ott; Cynthia Kassab; Anantha Marisetty; Yuuri Hashimoto; Jun Wei; Daniel Zamler; Jia-Shiun Leu; Karl-Heinz Tomaszowski; Aria Sabbagh; Dexing Fang; Pravesh Gupta; Waldemar Priebe; Rafal J Zielinski; Jared K Burks; James P Long; Ling-Yuan Kong; Gregory N Fuller; John DeGroot; Erik P Sulman; Amy B Heimberger Journal: Clin Cancer Res Date: 2020-06-30 Impact factor: 13.801
Authors: Amro K Bin Abdulrahman; Khalid A Bin Abdulrahman; Yousef R Bukhari; Abdulaziz M Faqihi; Juan Gabriel Ruiz Journal: Brain Behav Date: 2019-08-29 Impact factor: 2.708
Authors: Aaron Bower; Fang-Chi Hsu; Kathryn E Weaver; Caleb Yelton; Rebecca Merrill; Robert Wicks; Mike Soike; Angelica Hutchinson; Emory McTyre; Adrian Laxton; Stephen Tatter; Christina Cramer; Michael Chan; Glenn Lesser; Roy E Strowd Journal: Neurooncol Pract Date: 2020-03-24
Authors: Katherine L Eales; Edward A Wilkinson; Garth Cruickshank; James H R Tucker; Daniel A Tennant Journal: Sci Rep Date: 2018-09-25 Impact factor: 4.379